Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults.

Buckley MS, Feldman JP.

Pharmacotherapy. 2010 Jul;30(7):728-40. doi: 10.1592/phco.30.7.728. Review.

PMID:
20575636
2.

Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.

Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D.

Health Technol Assess. 2009 Oct;13(49):1-320. doi: 10.3310/hta13490. Review.

3.

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group.

Ann Intern Med. 2008 Oct 21;149(8):521-30. Erratum in: Ann Intern Med. 2009 Jan 6;150(1):63. Ann Intern Med. 2009 Sep 15;151(6):435.

PMID:
18936500
4.

A new epoprostenol formulation for the treatment of pulmonary arterial hypertension.

Fuentes A, Coralic A, Dawson KL.

Am J Health Syst Pharm. 2012 Aug 15;69(16):1389-93. doi: 10.2146/ajhp110687. Review.

PMID:
22855104
5.

Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.

Kemp K, Savale L, O'Callaghan DS, Jaïs X, Montani D, Humbert M, Simonneau G, Sitbon O.

J Heart Lung Transplant. 2012 Feb;31(2):150-8. doi: 10.1016/j.healun.2011.11.002. Epub 2011 Dec 3.

PMID:
22138355
6.

[Ten years' experience in continuous intravenous epoprostenol therapy in severe pulmonary arterial hypertension].

Pombo Jiménez M, Escribano Subías P, Tello de Meneses R, Gómez-Sánchez MA, Delgado Jiménez J, Dalmau González-Gallarza R, Lázaro Salvador M, Hernández Rodríguez I, Tascón Pérez J, Sáenz de la Calzada C.

Rev Esp Cardiol. 2003 Mar;56(3):230-5. Spanish.

7.

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G.

Eur Respir J. 2004 Sep;24(3):353-9.

8.

Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.

Hall SM, Davie N, Klein N, Haworth SG.

Eur Respir J. 2011 Oct;38(4):851-60. doi: 10.1183/09031936.00167010. Epub 2011 Mar 15.

9.

Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension.

Lambert O, Bandilla D.

Drug Des Devel Ther. 2012;6:235-44. doi: 10.2147/DDDT.S31628. Epub 2012 Sep 17.

10.

Epoprostenol use for pulmonary arterial hypertension in the palliative care setting.

Wozencraft CP, Coyne PJ, Grinnan DC, Morel TD, Muzevich KM, Smith TJ.

J Palliat Med. 2012 May;15(5):619-22. doi: 10.1089/jpm.2011.0182. Epub 2012 Mar 6.

PMID:
22394366
11.

How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?

Barst R.

Int J Clin Pract Suppl. 2010 Nov;(168):23-32. doi: 10.1111/j.1742-1241.2010.02525.x. Review.

PMID:
20939843
12.

Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.

Melnick L, Barst RJ, Rowan CA, Kerstein D, Rosenzweig EB.

Am J Cardiol. 2010 May 15;105(10):1485-9. doi: 10.1016/j.amjcard.2009.12.075. Epub 2010 Apr 8.

PMID:
20451700
13.

Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.

Demerouti EA, Manginas AN, Athanassopoulos GD, Karatasakis GT, Leontiadis ED, Pavlides GS.

Respir Care. 2013 Feb;58(2):e1-5. doi: 10.4187/respcare.01752. Review.

14.

Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension.

Rich S, Pogoriler J, Husain AN, Toth PT, Gomberg-Maitland M, Archer SL.

Chest. 2010 Nov;138(5):1234-9. doi: 10.1378/chest.09-2815.

15.

Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol.

Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, Kral KM, Raphiou IH, Crater GD.

J Rheumatol. 2009 Oct;36(10):2244-9. doi: 10.3899/jrheum.081277. Epub 2009 Sep 1.

PMID:
19723905
16.

Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension.

Akagi S, Nakamura K, Miyaji K, Ogawa A, Kusano KF, Ito H, Matsubara H.

Circ J. 2010 Oct;74(10):2200-5. Epub 2010 Aug 6.

17.

Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension.

Chin KM, Channick RN, de Lemos JA, Kim NH, Torres F, Rubin LJ.

Chest. 2009 Jan;135(1):130-136. doi: 10.1378/chest.08-1323. Epub 2008 Aug 21.

PMID:
18719056
18.

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.

Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, Humbert M, Rainisio M, Rubin LJ, Simonneau G.

Thorax. 2005 Dec;60(12):1025-30. Epub 2005 Jul 29.

19.

The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons.

Hall H, Côté J, McBean A, Purden M.

Heart Lung. 2012 Jan-Feb;41(1):35-43. doi: 10.1016/j.hrtlng.2011.05.007. Epub 2011 Jul 23.

PMID:
21784527

Supplemental Content

Support Center